Growth-attenuation therapy: Principles for practice

Pediatrics

Volumn 123, Issue 6, 2009, Pages 1556-1561

  Allen, David B ^a,d   Kappy, Michael ^b   Diekema, Douglas ^c   Fost, Norman ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Children's Hospital Colorado   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UW American Family Children's Hospital   (United States)

Author keywords

Cognitive disability; Ethics; Growth; Growth attenuation

Indexed keywords

ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; TESTOSTERONE;

AREOLAR HYPERPIGMENTATION; BODY HEIGHT; BREAKTHROUGH BLEEDING; BREAST CANCER; CHILD CARE; CHILD GROWTH; COGNITIVE DEFECT; DRUG SAFETY; ESTROGEN THERAPY; FAMILY; HOME; HUMAN; HYPERPIGMENTATION; NAUSEA; PEDIATRICIAN; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SHORT STATURE; SIDE EFFECT; UTERUS CANCER; WEIGHT GAIN;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BODY HEIGHT; BODY WEIGHT; BONE DEVELOPMENT; CAREGIVERS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DISABLED CHILDREN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; ETHICS COMMITTEES; ETHICS, MEDICAL; FEMALE; GROWTH PLATE; HOME NURSING; HUMANS; INFANT; MALE; TREATMENT OUTCOME;

EID: 66249086948     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-2951     Document Type: Review

References (27)

1. Gunther DF, Diekema D. Attenuating growth in children with profound developmental disability: a new approach to an old dilemma. Arch Pediatr Adolesc Med. 2006;160(10):1013-1017 (Pubitemid 44520630)
2. Nilsson O, Marino R, De Luca F, Phillip M, Baron J. Endocrine regulation of the growth plate. Horm Res. 2005;64(4):157-165 (Pubitemid 41642759)
3. Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989;320(8):496-502 (Pubitemid 19062525)
4. Takano H, Aizawa T, Irie T, Itoi E, Kokubun S, Roach HI. Normal bone growth requires optimal estrogen levels: negative effects of both high and low dose estrogen on the number of growth plate chondrocytes. Tohoku J Exp Med. 2008;214(3):269-280
5. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689-3698
6. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [published correction appears in N Engl J Med. 1995;332(2):131]. N Engl J Med. 1994;331(16):1056-1061
7. Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocr Rev. 1998;19(5):540-558 (Pubitemid 28467710)
8. Lee JM, Howell JD. Tall girls: the social shaping of a medical therapy. Arch Pediatr Adolesc Med. 2006;160(10):1035-1039 (Pubitemid 44520633)
9. Bierich JR. Estrogen treatment of girls with constitutional tall stature. Pediatrics. 1978;62(6 pt 2):1196-1201 (Pubitemid 9091373)
10. Venn A, Epid GD, Hosmer T, et al. Oestrogen treatment for tall stature in girls: estimating the effect on height and the error in height prediction. Clin Endocrinol (Oxf). 2008;68(6):926-929
11. Barnard ND, Scialli AR, Bobela S. The current use of estrogens for growth-suppressant therapy in adolescent girls. J Pediatr Adolesc Gynecol. 2002;15(1):23-26 (Pubitemid 34245574)
12. Conte FA, Grumbach MM. Estrogen use in children and adolescents: a survey. Pediatrics. 1978;62(6 pt 2):1091-1097 (Pubitemid 9091357)
13. Mack TM. Postmenopausal carcinoma as a result of estrogen treatment: survey of evidence. Pediatrics. 1978;62(6 pt 2):1104-1113 (Pubitemid 9091359)
14. de Waal WJ, Torn M, de Muinck Keizer-Schrama SM, Aarsen RS, Drop SL. Long term sequelae of sex steroid treatment in the management of constitutionally tall stature. Arch Dis Child. 1995;73(4):311-315
15. Hamilton AS, Mack TM. Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med. 2003;348(23):2313-2322 (Pubitemid 36638105)
16. Allen DB, Rose SR, Reither EO. Normal growth and growth disorders. In: Kappy MS, Allen DB, Geffner ME, eds. Principles and Practice of Pediatric Endocrinology. Springfield, IL: Charles Thomas; 2005:77-203
17. Coleman G. The irreversible disabling of a child: the "Ashley treatment." Natl Cathol Bioeth Q. 2007;7(4):711-728
18. Ouellette AR. Growth attenuation, parental choice, and the rights of disabled children: lessons from the Ashley X case. Available at: http://ssrn.com/abstract=1084903. Accessed August 29, 2008
19. Brosco JP, Feudtner C. Growth attenuation: a diminutive solution to a daunting problem. Arch Pediatr Adolesc Med. 2006;160(10):1077-1078 (Pubitemid 44520639)
20. Fost N. Ethical dilemmas in medical innovation and research: distinguishing experimentation from practice. Semin Perinatol. 1998; 22(3):223-232 (Pubitemid 28294763)
21. Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003;290(7):905-911 (Pubitemid 37430462)
22. Lindemann H, Nelson JL. The romance of the family. Hastings Cent Rep. 2008;38(4):19-21
23. Savalescu J. The proper place of values in the delivery of medicine. Am J Bioeth. 2007;7(12):21-22; discussion W1-W2
24. Disability Rights Education and Defense Fund. Modify the system, not the person. Available at: http://dredf.org/news/ashley.shtml. Accessed August 29, 2008
25. Ellis EB. Disabling children with disabilities. Arch Pediatr Adolesc Med. 2007;161(4):419 (Pubitemid 46556382)
26. Macklin R. Dignity is a useless concept. BMJ. 2003;327(7429):1419-1420 (Pubitemid 38045809)
27. Washington Protection and Advocacy System. "Ashley treatment" investigation. Available at: www.disabilityrightswa.org/news-1/ashley-treatment- investigation. Accessed August 29, 2008